Best Growth Stock to Buy Right Now: Eli Lilly vs. Vertex Pharmaceuticals

Eli Lilly (NYSE: LLY) and Vertex Pharmaceuticals (NASDAQ: VRTX) have several things in common. Both are among the more prominent drugmakers in the world, and both have delivered market-beating returns over the past decade, although the larger Eli Lilly has performed much better on that front. Investors choosing between these two stocks can hardly go wrong, but which will be the better performer over the next five to 10 years? Let's try to answer that question.Image source: Getty Images.Eli Lilly currently leads the rapidly growing weight-loss market. The company's tirzepatide, sold under the brand name Zepbound, is now the world's best-selling drug. Over the next two years, the pharmaceutical leader should add several weight loss products to its lineup. The company is gearing up to launch orforglipron, an oral GLP-1, which could earn the green light in the second quarter. The healthcare giant also posted strong phase 3 results for retatrutide, another promising weight-loss candidate, in December.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool